Humulin N

Humulin N is a recombinant human insulin (rDNA) marketed as an injectable solution, supplied in multiple strengths for subcutaneous administration. It belongs to the insulin class of antidiabetic agents and is prescribed by health‑care professionals in the European Union for the management of blood glucose in patients with diabetes mellitus. The product is a prescription‑only medication and is not classified as a controlled substance or schedule.

Humulin N is indicated for the long‑acting control of blood glucose in diabetes.

- Type 1 diabetes mellitus in adults and children when basal insulin is required. - Type 2 diabetes mellitus as part of basal insulin therapy, alone or with oral agents. - Adjunct to mealtime insulin for patients needing both basal and prandial coverage. - Use during pregnancy only when benefits outweigh risks, under specialist supervision. - May be employed in insulin‑pump therapy where compatible formulations are approved.

Like other insulin products, Humulin N may cause adverse reactions ranging from mild to severe.

Common: - Mild hypoglycemia, characterized by shakiness, sweating, or dizziness. - Redness, swelling, or itching at the injection site. - Small amounts of localized fat loss or gain (lipodystrophy). - Transient weight gain due to fluid retention.

Serious: - Severe hypoglycemia with loss of consciousness or seizures. - Immediate allergic reaction such as hives, bronchospasm, or anaphylaxis. - Significant low potassium (hypokalemia) that may affect heart rhythm. - Persistent edema or heart failure exacerbation linked to insulin therapy.

Healthcare providers should consider several precautions before prescribing Humulin N to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review history of hypoglycemia unawareness or frequent episodes. - Adjust dose during periods of illness, surgery, or reduced food intake. - Monitor blood glucose closely when initiating therapy or changing dose. - Counsel patients on proper injection technique and rotation of sites. - Evaluate pregnancy status; use only if benefits outweigh potential risks.

Humulin N can interact with other medicines, affecting glucose control or increasing adverse effects.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms. - MAO‑A inhibitors that can potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which raise blood glucose and may require higher insulin doses. - Diuretics that can cause electrolyte shifts influencing insulin action.